Clinical application value of a five-gene locus detection kit including CYP2D6*10 and CYP2C9*3 in individualized cardiovascular medication

Key Loci in Cardiovascular Pharmacogenomics

The pharmacokinetics and pharmacodynamics of commonly used clinical cardiovascular drugs such as metoprolol, losartan, and enalapril are influenced by multiple gene polymorphisms. CYP2D6 is a key enzyme for metabolizing β-blockers (metoprolol, propranolol) and certain calcium channel blockers. In Asian populations, the frequency of the CYP2D6*10 (100C>T) reduced-function allele is relatively high, and carriers may have elevated plasma concentrations when taking standard doses of metoprolol, increasing the risk of bradycardia. CYP2C9*3 (1075A>C) leads to decreased enzyme activity, affecting the metabolism of warfarin and certain angiotensin II receptor antagonists (such as losartan). ADRB1 (1165G>C) (i.e., Arg389Gly) is associated with responsiveness to β-blockers, and Gly389 carriers may have a weaker antihypertensive response to metoprolol. AGTR1 (1166A>C) affects angiotensin II receptor expression and is associated with target organ damage and differences in drug efficacy. The ACE I/D polymorphism (insertion/deletion) is closely related to the efficacy of ACE inhibitors and the risk of cardiovascular events.

Clinical Interpretation of Kit Test Results and Medication Reference

After obtaining the patient's genotypes for the above five loci using this kit, clinical pharmacists can adjust the medication regimen based on genotype combinations. For example, for patients with CYP2D6*10/*10 (poor metabolizer), metoprolol should be started at a low dose (e.g., 12.5 mg/day) and adjusted according to heart rate; for patients with CYP2C9*3/*3 (slow metabolizer), losartan should be reduced in dose or replaced with a drug not metabolized by CYP2C9; for those with ADRB1 1165G>C detected as CC genotype (Gly/Gly), consideration may be given to increasing the β-blocker dose or switching to another class of antihypertensive drug; patients with the ACE D/D genotype have a higher risk of hypotension when using ACE inhibitors and require cautious initiation. C allele carriers of AGTR1 1166A>C may respond better to ARBs. The one-time multi-locus detection provided by this kit is more efficient than testing individual loci separately and is suitable as a tool for pre-treatment assessment in hypertension, coronary heart disease, and other conditions.

Key Points for Combining Detection Methods with Clinical Practice

This kit uses fluorescence PCR-capillary electrophoresis, and the results can be directly used in clinical reports, but attention should be paid to the following: genetic testing only provides genetic predisposition and cannot replace therapeutic drug monitoring and clinical observation. Physicians should make comprehensive judgments in conjunction with the patient's liver function, kidney function, concomitant medications, and other factors. For CYP2D6*10 and CYP2C9*3, metabolic phenotypes can be inferred from genotypes, but interindividual phenotypic differences require consideration of other factors. The association of the D/D type in ACE I/D testing with myocardial hypertrophy and coronary heart disease risk should be assessed in conjunction with family history. The kit instructions should include clear genotype interpretation charts and corresponding medication recommendation levels (such as CPIC guideline recommendations) to facilitate rapid application by clinical personnel.

Clinical Benefits and Limitations of Testing

This testing kit can help identify patients who respond poorly to standard doses or are prone to adverse reactions, thereby reducing unnecessary dose adjustment cycles and lowering the incidence of adverse drug events. Especially in elderly patients and complex medication scenarios with multiple underlying diseases, genotyping can assist in achieving truly individualized treatment. However, test results cannot explain all differences in drug efficacy, and the level of clinical evidence for some loci (such as ADRB1) still requires further research. Therefore, this kit is positioned as a clinical auxiliary decision-making tool, not the sole basis. Rational use must be established on the basis of full communication and informed consent from physicians.